<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01530360</url>
  </required_header>
  <id_info>
    <org_study_id>SBP010911</org_study_id>
    <nct_id>NCT01530360</nct_id>
  </id_info>
  <brief_title>Cerebral Oxygenation to Guide Medical Interventions in Extremely Preterm Infants</brief_title>
  <acronym>SafeBoosC-p</acronym>
  <official_title>Safeguarding the Brains of Our Smallest Children - a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gorm Greisen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Elsass Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Copenhagen Trial Unit, Center for Clinical Intervention Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Katholieke Universiteit Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College Cork</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Milan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitair Medisch Centrum Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Witten/Herdecke</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Uppsala</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Regional tissue oxygenation (rStO2) can be monitored by near-infrared spectroscopy. The
      investigators planned a SafeBoosC phase II trial to test if a reduction of the burden of
      hyper- and hypoxia can be accomplished during the first three days of life in infants born
      before 28 completed weeks of gestation. The investigators developed a treatment guideline and
      a randomised trial design to evaluate if cerebral rStO2 spent out of range in %hours can be
      reduced by 50%. The present trial is a non-randomised pilot study of the intervention in 10
      infants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of medical management elicited by cerebral oxygenation out of range</measure>
    <time_frame>0-72 hours of life</time_frame>
    <description>Recording of the type of change of management as defined by the treatment guideline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse device effects</measure>
    <time_frame>0-72 hours</time_frame>
    <description>Expected and unexpected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>burden of hypo-and hyperoxia</measure>
    <time_frame>0-72 hours</time_frame>
    <description>measured as %hours out of the target range (55-85%)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Premature Infants</condition>
  <condition>Near-infrared Spectroscopy</condition>
  <condition>Oximetry</condition>
  <arm_group>
    <arm_group_label>cerebral oximetry + treatment guideline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cerebral oximetry applied as soon as possible after birth and continued until 72 hours of life Clinical staff administer the routine medical management according to local practice as well as respond to out-of-range values with the help of the treatment guideline</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>cerebral oximeter</intervention_name>
    <description>INVOS 5100c + SAFB-SM SOMASENSOR NONIN EQUANOX 7600 + sensor model 8000CA</description>
    <arm_group_label>cerebral oximetry + treatment guideline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  gestational age at birth less than 28 completed weeks

          -  cerebral oximeter in place at 3 hours after birth

        Exclusion Criteria:

          -  decision not to provide full life support
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gorm Greisen, MD,DMSci</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Neonatology, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Greisen G, Leung T, Wolf M. Has the time come to use near-infrared spectroscopy as a routine clinical tool in preterm infants undergoing intensive care? Philos Trans A Math Phys Eng Sci. 2011 Nov 28;369(1955):4440-51. doi: 10.1098/rsta.2011.0261. Review.</citation>
    <PMID>22006900</PMID>
  </reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2012</study_first_submitted>
  <study_first_submitted_qc>February 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2012</study_first_posted>
  <last_update_submitted>December 7, 2012</last_update_submitted>
  <last_update_submitted_qc>December 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Gorm Greisen</investigator_full_name>
    <investigator_title>professor,head of department</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

